Market research
GERN Geron Corporation
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 608M
- P/E ratio
- Not available
- Analyst target
- 3.625
- Dividend yield
- Not available
- Beta
- 0.61
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 608M
- P/E ratio
- Not available
- Analyst target
- 3.625
- Dividend yield
- Not available
- Beta
- 0.61
About
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Research context
Geron Corporation appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the GERN discussion.
5 years, 7 months ago
Geron Corporation is currently in a long term downtrend where the price is trading 17.7% below its 200 day moving average.
From a valuation standpoint, the stock is 29.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1738.2.
Geron Corporation's total revenue sank by 70.8% to $50K since the same quarter in the previous year.
Its net income has increased by 18.2% to $-24M since the same quarter in the previous year.
Finally, its free cash flow fell by 20.8% to $-13M since the same quarter in the previous year.
Based on the above factors, Geron Corporation gets an overall score of 1/5.